Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia
In clinical trials of drugs, including sodium-glucose co-transporter-2 inhibitors (SGLT2), the main reason for the discontinuation of the therapy are side effects. However, there are additional factors that affect the discontinuation of the therapy in real clinical practice. This paper presents asse...
Main Authors: | D. A. Lebedev, A. Yu. Babenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-09-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2639 |
Similar Items
-
Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
by: Osman İnan, et al.
Published: (2022-07-01) -
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
by: Johan Mårtensson, et al.
Published: (2023-05-01) -
Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis
by: Lakshmi Nagendra, et al.
Published: (2024-04-01) -
Inhibitors of the sodium-glucose transporter type 2 and new possibilities for managing vascular age in patients with type 2 diabetes mellitus
by: I. Sh. Khalimov, et al.
Published: (2021-09-01) -
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
by: Sanjay Kalra, et al.
Published: (2018-01-01)